Literature DB >> 8058133

Neurologic deterioration in noncomatose patients with supratentorial intracerebral hemorrhage.

S A Mayer1, R L Sacco, T Shi, J P Mohr.   

Abstract

OBJECTIVE: To determine the frequency, time course, and predictors of neurologic deterioration (ND) in noncomatose patients with supratentorial intracerebral hemorrhage (ICH).
BACKGROUND: Patients with worsening ICH may benefit from therapy aimed at reducing mass effect due to active bleeding or cerebral edema.
METHODS: We analyzed 46 noncomatose (Glasgow Coma Scale [GCS] score > or = 8) patients with ICH in the Stroke Data Bank (SDB). All subjects were examined within 24 hours of onset (mean, 13.6 hours) and were prospectively followed with serial examinations during hospitalization. ND was defined as (1) a > or = 2-point decrease in the GCS score, (2) a > or = 1-point increase in the SDB weakness score, or (3) a new deficit, unrelated to medical or surgical complications.
RESULTS: ND occurred in 15 of 46 patients (33%). The frequency of ND was greatest on the first hospital day (eight of 15 patients) and decreased progressively thereafter. Patients with ND had larger hemorrhages (mean volume, 45 ml versus 16 ml, p < 0.01) and more frequently demonstrated marked mass effect (60% versus 19%, p < 0.01) on initial CT than those with stable deficits, but did not differ with regard to mean GCS score, mean blood pressure, or other clinical variables on admission. Hematoma enlargement was judged to be the cause of worsening in four of 15 (27%) patients. Thirty-day case fatality was 47% in those with ND compared with 3% in those with stable deficits (p = 0.001).
CONCLUSIONS: ND occurs in one-third of noncomatose patients with supratentorial ICH and carries a poor prognosis. Large hematoma volume on CT, rather than clinical predictors, identifies patients at high risk for subsequent worsening.

Entities:  

Mesh:

Year:  1994        PMID: 8058133     DOI: 10.1212/wnl.44.8.1379

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  57 in total

1.  Blood Pressure Management in Intracranial Hemorrhage: Current Challenges and Opportunities.

Authors:  Cheryl Carcel; Shoichiro Sato; Craig S Anderson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-04

2.  Only very early oxygen therapy attenuates posthemorrhagic edema formation and blood-brain barrier disruption in murine intracerebral hemorrhage.

Authors:  Wei Zhou; Marilena Marinescu; Roland Veltkamp
Journal:  Neurocrit Care       Date:  2015-02       Impact factor: 3.210

3.  Poor correlation between perihematomal MRI hyperintensity and brain swelling after intracerebral hemorrhage.

Authors:  Allyson R Zazulia; Tom O Videen; Michael N Diringer; William J Powers
Journal:  Neurocrit Care       Date:  2011-12       Impact factor: 3.210

4.  Optimizing referral practices for patients with non-traumatic intracerebral hemorrhage.

Authors:  N Scott Litofsky; Joshua Matthews; Michael L Wolak; M Mohsin Shah; Itay Melamed; Lori A Thombs
Journal:  Mo Med       Date:  2010 May-Jun

Review 5.  Treatment targets in intracerebral hemorrhage.

Authors:  Navdeep Sangha; Nicole R Gonzales
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

Review 6.  Use of hypothermia in the intensive care unit.

Authors:  Jesse J Corry
Journal:  World J Crit Care Med       Date:  2012-08-04

Review 7.  The use of targeted temperature management for elevated intracranial pressure.

Authors:  Jesse J Corry
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

8.  Intracerebral hemorrhage: clinical overview and pathophysiologic concepts.

Authors:  Fred Rincon; Stephan A Mayer
Journal:  Transl Stroke Res       Date:  2012-04-21       Impact factor: 6.829

9.  Current treatment options for intracerebral hemorrhage.

Authors:  Fred Rincon; Stephan A Mayer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-06

Review 10.  Clinical review: Critical care management of spontaneous intracerebral hemorrhage.

Authors:  Fred Rincon; Stephan A Mayer
Journal:  Crit Care       Date:  2008-12-10       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.